Educate HCP’s on frailty assessment
Discuss clinical experience and Real World Evidence for therapeutic agents in the frail and elderly patient population.
Use of triplets in Frail and elderly population
New maintenance treatments in multiple myeloma in newly diagnosed and RRMM
Date: Friday, November 13th, 2020 at 3:00 PM EDT / 12:00 PM PDT
Speaker: Dr. Ajai Chari
Chair: Dr. Kevin Song
This webinar has been made possible through sponsorship from Takeda Canada
Dr. Ajai Chari completed his medical degree at the UCLA School of Medicine. His clinical focus is on patients with multiple myeloma and other plasma cell disorders, and he has also published and lectured extensively on topics relating to these diseases. Dr Chari is involved in several clinical trials investigating new drug regimens, and he oversees a program that played a pivotal role in the approval of the five newest drugs used for the treatment of multiple myeloma. Dr. Chari is Professor of Medicine, Director of Clinical Research in the Multiple Myeloma Program, and Associate Director of Clinical Research at the Mt. Sinai Cancer Clinical Trials Office in New York, New York
Dr. Kevin Song is currently a member of the Leukemia / Bone Marrow Transplant Program of British Columbia and Clinical Associate Professor in the Department of Medicine in the University of British Columbia. He graduated from McGill University Medical School in 1995. He completed his hematology sub-specialization at the University of British Columbia followed by fellowships with the Leukemia Bone Marrow Transplant Program of British Columbia and the University of Toronto Autologous Blood and Marrow Transplant Program at Princess Margaret Hospital. He has been in his current position since 2002. His areas of interest are in the study of therapies for myeloma and lymphomas. He acts as the lead physician at BC Cancer for Multiple Myeloma, running clinical trials and developing provincial treatment protocols and algorithms. He is currently Vice-Chair of the Board of the Canada Myeloma Research Group. He is also actively involved in CAR T-cell therapies acting as the local PI for studies as well as being involved in committees for the implementation of CAR T-cells as standard therapies.
For more information, please send requests to Robyn Leonard at firstname.lastname@example.org.